NCT04133337

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

One-arm Exploratory Study on the Efficacy and Safety of Apatinib Combined With SHR-1210 Injection (PD-1 Antibody) in the Treatment of Removable IB-IIIA Non-small Cell Lung Cancer

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Sichuan Cancer Hospital and Research Institute · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study was to investigate the safety and efficacy of SHR-1210 in combination with the anti-vascular survival target drug apatinib in patients with resectable NSCLC, and to provide new treatment options for neoadjuvant therapy in patients with the period IB-IIIA NSCLC.

Conditions

• Lung Diseases
• Neoplasms
• Respiratory Tract Diseases
• Thoracic Neoplasms
• Non-small-cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Apatinib	Apatinib Mesylate Tablets
DRUG	SHR-1210	Camrelizumab for Injection

Timeline

• Start date: 2019-11-01
• Primary completion: 2020-06-01
• Completion: 2021-06-01
• First posted: 2019-10-21
• Last updated: 2019-10-21

Locations

1 site across 1 country: China